Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) EBT Margin (2016 - 2025)

Cytosorbents' EBT Margin history spans 15 years, with the latest figure at 70.46% for Q4 2025.

  • Quarterly results put EBT Margin at 70.46% for Q4 2025, down 9739.0% from a year ago — trailing twelve months through Dec 2025 was 42.59% (down 1300.0% YoY), and the annual figure for FY2025 was 25.92%, up 410.0%.
  • EBT Margin for Q4 2025 was 70.46% at Cytosorbents, down from 37.65% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 167.57% in Q4 2023 to a low of 150.42% in Q3 2022.
  • The 5-year median for EBT Margin is 56.09% (2023), against an average of 50.34%.
  • The sharpest move saw EBT Margin surged 18736bps in 2023, then tumbled -14063bps in 2024.
  • Year by year, EBT Margin stood at 93.14% in 2021, then soared by 79bps to 19.79% in 2022, then soared by 947bps to 167.57% in 2023, then plummeted by -84bps to 26.94% in 2024, then tumbled by -362bps to 70.46% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 70.46%, 37.65%, and 44.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.